TNG908 shows selectiveantitumor activity when dosed orally in mouse xenograft models, andits physicochemical properties are amenable for crossing the blood–brainbarrier (BBB), supporting clinical study for the treatment of bothCNS and non-CNS tumors with MTAP loss. The gene discussed is MTAP; the disease is central nervous system neoplasm.